美国 · 平台与数据 · Briefing.com
Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)
Disc Medicine (IRON) is surging today after announcing that its pivotal Phase 3 APOLLO trial of bitopertin met both co-primary and all secondary endpoints in patients with…
在 Briefing.com 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.briefing.com)
